Skip to contentN
Niagen Bioscience, Inc.
N
NAGENiagen Bioscience, Inc. Q2 2015 · 10-Q
Revenue$6.10M$6.10M+58.2% vs Q2 2014 Net Income-$315.19K-$315.19KN/M vs Q2 2014 EPS Diluted-$0.01-$0.01N/M vs Q2 2014 Gross Profit$2,470,692+76.6% Operating Income
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Niagen Bioscience, Inc. · CIK 1386570 · Engraved from SEC EDGAR
Margins · derivedGross margin40.5%+4.2 pt vs Q2 2014
Operating margin-3.0%+39.5 pt vs Q2 2014
Net margin-5.2%+37.7 pt vs Q2 2014
ended Jul 4, 2015 · filed Aug 13, 2015 · 40 d after period end